111 related articles for article (PubMed ID: 1958489)
1. The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release.
Nawarawong W; Wyshock E; Meloni FJ; Weitz J; Schmaier AH
Br J Haematol; 1991 Oct; 79(2):296-301. PubMed ID: 1958489
[TBL] [Abstract][Full Text] [Related]
2. An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.
Llobet D; Borrell M; Vila L; Vallvé C; Felices R; Fontcuberta J
Haematologica; 2007 Feb; 92(2):e17-9. PubMed ID: 17405747
[TBL] [Abstract][Full Text] [Related]
3. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
Al-Mondhiry H; Galanakis D
J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
[TBL] [Abstract][Full Text] [Related]
4. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
Lane DA; Cuddigan B; VanRoss M; Kakkar VV
Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
[TBL] [Abstract][Full Text] [Related]
5. An abnormal fibrinogen with delayed fibrinopeptide A release.
Lane DA; VanRoss M; Kakkar VV; Bottomley KJ; Dhir K; Holt LP; MacIver JE
Br J Haematol; 1980 Sep; 46(1):89-98. PubMed ID: 7426452
[TBL] [Abstract][Full Text] [Related]
6. The release of small amounts of fibrinopeptide-B (FPB) is of critical importance for the thrombin clotting time.
Holm B; Kierulf P; Godal HC
Thromb Res; 1986 May; 42(4):517-26. PubMed ID: 3715815
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg-->cys substitution.
Loreth RM; Meyer M; Albert FW
Haemostasis; 2001; 31(1):12-7. PubMed ID: 11408744
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.
Gris JC; Schved JF; Branger B; Aguilar-Martinez P; Vécina F; Oulès R; Sarlat C; Fourcade J
Blood Coagul Fibrinolysis; 1992 Oct; 3(5):519-29. PubMed ID: 1450318
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.
Branson HE; Schmer G; Theodor I; Pirkle H
Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
[TBL] [Abstract][Full Text] [Related]
13. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
Siebenlist KR; Prchal JT; Mosesson MW
Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.
Gralnick HR; Givelber HM; Shainoff JR; Finlayson JS
J Clin Invest; 1971 Sep; 50(9):1819-30. PubMed ID: 5564389
[TBL] [Abstract][Full Text] [Related]
15. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules.
Jandrot-Perrus M; Aurousseau MH; Rabiet MJ; Josso F
Thromb Res; 1982 Sep; 27(6):659-70. PubMed ID: 6217586
[TBL] [Abstract][Full Text] [Related]
17. Clotting of bovine fibrinogen. Calcium binding to fibrin during clotting and its dependence on release of fibrinopeptide B.
Mihalyi E
Biochemistry; 1988 Feb; 27(3):967-76. PubMed ID: 3365373
[TBL] [Abstract][Full Text] [Related]
18. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].
Furlan M; Leupin L; Biasiutti FD; Lämmle B
Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701
[TBL] [Abstract][Full Text] [Related]
19. Acquired coagulation inhibitor delaying fibrinopeptide release.
Marciniak E; Greenwood MF
Blood; 1979 Jan; 53(1):81-92. PubMed ID: 758215
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
